Publications
Tempero M. I'm Conflicted. Are You? Journal of the National Comprehensive Cancer Network : JNCCN. 2018. PMID: 30442729
Nanjo S, Bivona TG. Circulating tumor DNA analysis in patients with EGFR mutant lung cancer. Journal of thoracic disease. 2018. PMID: 30631555
Illei PB, Wong W, Wu N, Chu L, Gupta R, Schulze K, Gubens MA. ALK Testing Trends and Patterns Among Community Practices in the United States. JCO precision oncology. 2018. PMID: 35135148
Mohler JL, Halabi S, Ryan ST, Al-Daghmin A, Sokoloff MH, Steinberg GD, Sanford BL, Eastham JA, Walther PJ, Morris MJ, Small EJ. Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series. Prostate cancer and prostatic diseases. 2018. PMID: 30385835
Gordon JW, Chen HY, Autry A, Park I, Van Criekinge M, Mammoli D, Milshteyn E, Bok R, Xu D, Li Y, Aggarwal R, Chang S, Slater JB, Ferrone M, Nelson S, Kurhanewicz J, Larson PEZ, Vigneron DB. Translation of Carbon-13 EPI for hyperpolarized MR molecular imaging of prostate and brain cancer patients. Magnetic resonance in medicine. 2018. PMID: 30375043
Kang H, Pettinga D, Schubert AD, Ladenson PW, Ball DW, Chung JH, Schrock AB, Madison R, Frampton GM, Stephens PJ, Ross JS, Miller VA, Ali SM. Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy. The oncologist. 2018. PMID: 30373905
Costa-Cabral S, Brough R, Konde A, Aarts M, Campbell J, Marinari E, Riffell J, Bardelli A, Torrance C, Lord CJ, Ashworth A. Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours. PloS one. 2018. PMID: 30365555
Munster P, Krop IE, LoRusso P, Ma C, Siegel BA, Shields AF, Molnár I, Wickham TJ, Reynolds J, Campbell K, Hendriks BS, Adiwijaya BS, Geretti E, Moyo V, Miller KD. Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study. British journal of cancer. 2018. PMID: 30361524
Hurvitz SA, Quek RGW, Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke E, Mina LA, Balmaña J, Fasching PA, Bhattacharyya H, Hannah AL, Robson ME, Wardley AM. Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial. European journal of cancer (Oxford, England : 1990). 2018. PMID: 30359909
Samuel Craig Brondfield, Hala Borno, Claire Mulvey, Li-Wen Huang, Pelin Cinar. Implementation of a fellow-initiated financial toxicity screening tool in medical oncology clinics. Journal of Clinical Oncology. 2018. PMID:
Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA, IMpassion130 Trial Investigators. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. The New England journal of medicine. 2018. PMID: 30345906
Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 2018. PMID: 30340047
Kwatra SG, Ständer S, Kang H. PD-1 Blockade-Induced Pruritus Treated with a Mu-Opioid Receptor Antagonist. The New England journal of medicine. 2018. PMID: 30332571
Wolf D, Bader CS, Barreras H, Copsel S, Pfeiffer BJ, Lightbourn CO, Altman NH, Komanduri KV, Levy RB. Superior immune reconstitution using Treg-expanded donor cells versus PTCy treatment in preclinical HSCT models. JCI insight. 2018. PMID: 30333311
Johns LE, Jones ME, Schoemaker MJ, McFadden E, Ashworth A, Swerdlow AJ. Response to 'Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study". British journal of cancer. 2018. PMID: 30327568
Koshkin VS, Garcia JA, Reynolds J, Elson P, Magi-Galluzzi C, McKenney JK, Isse K, Bishop E, Saunders LR, Balyimez A, Rashid S, Hu M, Stephenson AJ, Fergany AF, Lee BH, Haber GP, Dowlati A, Gilligan T, Ornstein MC, Rini BI, Abazeed ME, Mian OY, Grivas P. Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018. PMID: 30327311
Zhang J, Gajjala S, Agrawal P, Tison GH, Hallock LA, Beussink-Nelson L, Lassen MH, Fan E, Aras MA, Jordan C, Fleischmann KE, Melisko M, Qasim A, Shah SJ, Bajcsy R, Deo RC. Fully Automated Echocardiogram Interpretation in Clinical Practice. Circulation. 2018. PMID: 30354459
Spassov DS, Ruiz-Saenz A, Piple A, Moasser MM. A Dimerization Function in the Intrinsically Disordered N-Terminal Region of Src. Cell reports. 2018. PMID: 30304684
Karantanos T, Rooper L, Kang Y, Lin CT, Wenga P, Sagorsky S, Lauring J, Kang H. Clinical Benefit to an Aurora A Kinase Inhibitor in a Patient with Metastatic Integrase Interactor 1-Deficient Carcinoma. The oncologist. 2018. PMID: 30297384
Abou-Alfa GK, Borgman-Hagey AE, Kelley RK. Cabozantinib in Hepatocellular Carcinoma. The New England journal of medicine. 2018. PMID: 30281991